, Volume 14, Issue 6, pp 485-489
Date: 05 Dec 2009

Significance of sentinel lymph node biopsy in malignant melanoma: overview of international data

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


The notion of sentinel lymph node (SLN) mapping and its use during surgery for staging cancer was initially reported in 1992, in a study involving patients with malignant melanoma. To date SLN biopsy (SLNB) has emerged as a rational approach for staging regional lymph nodes in patients with clinically node-negative melanoma (stage I and II disease). The significance of SLNB as a staging and prognostic tool in melanoma is widely accepted. Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of the SLN remains very controversial. Whether SLNB improves survival in melanoma patients remains an open question.